All Stories

  1. Methods to predict heart failure in diabetes patients
  2. Variable effect of exercise training programme on cardiovascular outcomes in high-genetic-risk individuals with diabetes
  3. Plausible prediction of renoprotective effects of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney diseases
  4. Extracellular vesicles in heart failure
  5. Predictors of Kidney Function Outcomes and Their Relation to SGLT2 Inhibitor Dapagliflozin in Patients with Type 2 Diabetes Mellitus Who Had Chronic Heart Failure
  6. The effect of sglt-2 inhibitor dapagliflozin on adropin serum levels in patients with chronic heart failure and concomitant type 2 diabetes mellitus
  7. Cell-free DNA as a plausible biomarker of chronic kidney disease
  8. Extracellular Vesicles and Thrombogenicity in Atrial Fibrillation
  9. Vascular Functional Recovery and Reparation by Human Endothelial Progenitor Cells
  10. Vascular Functional Recovery and Reparation by Human Endothelial Progenitor Cells
  11. Reversibility of adverse cardiac remodeling in type 2 diabetes mellitus patients: focus on sodium-glucose cotransporter-2 inhibitors
  12. Biomarker-Based Guideline-Directed Medical Therapy of Heart Failure: The Gap Between Guidelines and Clinical Practice
  13. Biomarker-Based Guideline-Directed Medical Therapy of Heart Failure: The Gap Between Guidelines and Clinical Practice
  14. Challenging and opportunities in clinical implementation of circulating cardiac biomarkers in diabetes mellitus: the narrative review
  15. Antigen-presenting cell-derived extracellular vesicles in accelerating atherosclerosis
  16. Stem-Cell-Based Cardiac Regeneration: Is There a Place For Optimism in the Future?
  17. Endothelial cell-derived extracellular vesicles in atherosclerosis: the emerging value for diagnosis, risk stratification and prognostication
  18. Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers
  19. Extracellular Endothelial Cell-Derived Vesicles: Emerging Role in Cardiac and Vascular Remodeling in Heart Failure
  20. Altered adipocytokine profile predicts early stage of left ventricular remodeling in hypertensive patients with type 2 diabetes mellitus
  21. Diagnostic and therapeutic value of micro-RNAs in inflammatory bowel disease
  22. Efficacy of fixed dose of triple combination of perindopril-indapamide-amlodipine in obese patients with moderate-to-severe arterial hypertension: an open-label 6-month study
  23. P6603The predictive role of T786C single nucleotide polymorphism in endothelial no-synthase gene in late left ventricular remodeling after ST-segment elevation myocardial infarction
  24. Impaired function of fibroblast growth factor 23 / Klotho protein axis in prediabetes and diabetes mellitus: Promising predictor of cardiovascular risk
  25. Circulating platelet-derived vesicle in atrial fibrillation
  26. Altered signature of apoptotic endothelial cell-derived microvesicles predicts chronic heart failure phenotypes
  27. Platelet-derived vesicles: diagnostic and predictive value in cardiovascular diseases
  28. Platelet-Derived Vesicles in Hypertension: New Target for Risk Stratification?
  29. Vascular Access Surgery - Tips and Tricks
  30. Circulating vascular endothelial growth factor in ST-segment elevation myocardial infarction: from bench to bedside
  31. Prognostication of clinical outcomes in diabetes mellitus: Emerging role of cardiac biomarkers
  32. Dynamic changes of circulating vascular endothelial growth factor levels in ST-segment elevation myocardial infarction: Controversies in clinical interpretation
  33. Endothelial progenitor cell dysfunction in diabetes mellitus: new target for risk stratification and therapies?
  34. Cellular care and extracellular vesicles therapies of heart failure
  35. Platelet-derived vesicles in acute myocardial infarction
  36. Elevated levels of circulating soluble ST2 at discharge predict late adverse ventricular remodeling in patients with ST-segment elevation myocardial infarction
  37. The endothelial progenitor cell dysfunction in hypertension: the diagnostic and predictive values
  38. Association of growth-differentiation factor-15 with the number of circulating proangiogenic endothelial progenitor cells in patients with type 2 diabetes mellitus
  39. Neutrophil extracellular traps: The core player in vascular complications of diabetes mellitus
  40. Emerging Role of Galectin-3 in Pulmonary Artery Hypertension
  41. Reply to: Is serum uric acid a pretty accurate prognostic predictor of ST elevated acute coronary syndrome? Author: Alexander E. Berezin
  42. Circulating biomarkers in heart failure: diagnostic and prognostic importance
  43. Stem Cells and Stem Cells / Precursors-Derived Extracellular Vesicles in Heart Failure: What is Better for Cardiac Regeneration?
  44. Is serum uric acid a pretty accurate prognostic predictor of ST elevated acute coronary syndrome?
  45. Effect of Thymol against Fungi Deteriorating Mural Paintings at Tell Basta Tombs, Lower Egypt
  46. Circulating Biomarkers in Heart Failure
  47. The role of progenitor endothelial cell dysfunction in arterial hypertension
  48. Can C-reactive Protein Genetic Variants Identify Patients with Higher and Lower Cardiovascular Risk?
  49. Is Galectin-3 a Prognosticator of Severity and Clinical Outcomes of Pulmonary Artery Hypertension?
  50. The endothelial progenitor cell dysfunction in type 2 diabetes mellitus: the link with heart failure developing
  51. The Endothelial Progenitor Cell Dysfunction in Type 2 Diabetes Mellitus: The Link with Heart Failure Developing
  52. Progenitor Endothelial Cells in Pulmonary Arterial Hypertension
  53. Challenging role of neutrophil extracellular traps in vascular complications of diabetes mellitus
  54. The Impact of Endothelial Progenitor Cell Dysfunction in Heart Failure “Obesity Paradox”
  55. The Impact of Endothelial Progenitor Cell Dysfunction in Heart Failure “Obesity Paradox”
  56. The obesity phenotypes: emerging role of cardiac biomarkers
  57. Promising utilities of growth differentiation factor 15 in cardiovascular diseases
  58. Growth Differentiation Factor 15 As Promising Biomarker Of Poor Prognosis In Heart Failure
  59. Pattern of Micro Vesicles in Heart Failure: Novel Biomarker of Endothelial Dysfunction and Vascular Reparation
  60. Enterococcus faecium L-3 in Eradication of Helicobacter pylori: In-vivo and In-vitro
  61. Serum uric acid as a metabolic regulator of endothelial function in heart failure
  62. [BP.04.06] CIRCULATING ENDOTHELIAL-DERIVED APOPTOTIC MICROPARTICLES TO MONONUCLEAR PROGENITOR CELLS RATIO AS A PREDICTOR OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ACUTELY DECOMPENSATED HEART
  63. Dysfunction of Endothelial Cell Precursors in Heart Failure Development
  64. Uric Acid in Heart Failure: Controversy Factor in The Multiple Pathogenesis of The Disease
  65. P6493Non-classical phenotypes of circulating endothelial cell-derived progenitor cells predicts asymptomatic atherosclerosis metabolically unhealthy obesity
  66. Up-to-date clinical approaches of biomarkers’ use in heart failure
  67. 1314Endothelial progenitor cells and apoptotic endothelial cell-derived microparticle ratio predicts atrial fibrillation in chronic heart failure
  68. Abstracts
  69. Are inflammatory cytokines and angiogenic factors a predictive biomarker of diabetes retinopathy?
  70. The Controversial Role of Osteopontin in Vascular Calcification: From Bench to Bedside
  71. Abstract Book: ISEV2017
  72. Biosensing of Circulating Apoptotic Endothelial Cell Micro particles: The Impact in Risk Stratification of Obesity
  73. Circulating apoptotic endothelial cell-derived microparticles are predicted metabolically unhealthy obesity
  74. Assessment of nephroprotective action of angiotensin-converting enzyme inhibitor ramipril in patients with chronic glomerulonephritis
  75. Biosensing of periprocedural events in acute ST-segment elevation myocardial infarction patients with the erythrocyte-derived microparticles
  76. "Obesity Paradox" in Heart Failure: The Possible Role of Progenitor Endothelial Cell Dysfunction
  77. Microparticles in Chronic Heart Failure
  78. The predictive value of circulating apoptotic endothelial cell-derived micro particles in obesity progression?
  79. Number of Circulating Endothelial Progenitor Cells as a Predictive Biomarker of Heart Failure
  80. The Growth/Differentiation Factor-15 in Chronic Heart Failure: New Challenge in Biomarker-Guided Therapy?
  81. The Role of Vistafin in Diabetes-Induced Impairment of Endothelial Repair System
  82. The role of circulating endothelial progenitor cell dysfunction in pregnancy-induced hypertension
  83. Preconditioned Endothelial Progenitor Cells as Biomarker of Vascular Reparation?
  84. Novel Biomarkers in Prediction of Heart Failure Related Outcomes: From Bench to Bedside
  85. Current understanding of the role of new cardiac biomarkers in prediction of heart failure
  86. The placental cell-derived exosomes as a promising predictive biomarker of preeclampsia in symptomatic pregnancies
  87. Hypertension in Pregnancy: The Role of Circulating Endothelial Progenitor Cell Dysfunction
  88. Are Placental Cell-Derived Exosomes a Predictive Biomarker of Preeclampsia?
  89. Are Novel Cardiac Biomarkers Required in Prediction of Heart Failure Development and Outcomes?
  90. Could be Used an Immune Phenotypes of Circulating Endothelial Progenitor Cells as a Biomarker of Cardiovascular Disease?
  91. The Advanced Bright-field Light Optical Polarization Microscopy: Novel Coupling Method for Detection of Micro Vesicles
  92. Growth-Differentiation Factor-15 as Additional Prognostic Biomarkers in Heart Failure
  93. The Controversial Role of Serum Uric Acid in Cardiovascular Diseases
  94. The Endothelial Progenitor Cell Dysfunction: The Missed Predictor of Heart Failure Outcomes?
  95. Novel Biomarkers for Cardiovascular Risk in Obese Patients
  96. Combined methods for micro particles determining: are they useful?
  97. Osteopontin in Vascular Calcification: A Central Player or Accidental Witness?
  98. Coupling Analytical Methods for Detection of Microparticles: The Possibilities for Improvement
  99. Preconditioned Endothelial Progenitor Cells as Biomarker of Vascular Reparation?
  100. Progenitor Cell Dysfunction: The Role of Endothelial Precursors in Heart Failure
  101. Epigenetics in heart failure phenotypes
  102. Cardiac biomarkers in diabetes mellitus: New dawn for risk stratification?
  103. An association of serum vistafin level and number of circulating endothelial progenitor cells in type 2 diabetes mellitus patients
  104. Acute Cardiovascular Care 2016
  105. Biomarkers for cardiovascular risk in patients with diabetes: Table 1
  106. Links Between Concentrations of Serum 25-hydroxyvitamin D3 and the Numbers of Circulating Progenitor Mononuclear Cells in Patients With Metabolic Syndrome
  107. Endothelial progenitor cells dysfunction and impaired tissue reparation: The missed link in diabetes mellitus development
  108. Is rationale to decrease serum osteoprotegerin and fetuin-A in type 2 diabetes mellitus patients?
  109. Poster session 2Morphogenetic mechanisms290MiR-133 regulates retinoic acid pathway during early cardiac chamber specification291Bmp2 regulates atrial differentiation through miR-130 during early heart looping formationDevelopmental genetics294Associati...
  110. Data regarding association between serum osteoprotegerin level, numerous of circulating endothelial- derived and mononuclear-derived progenitor cells in patients with metabolic syndrome
  111. PS105 Impaired Immune Phenotype of Circulating Endothelial-Derived Microparticles in None-Diabetic Patients with Chronic Heart Failure
  112. Is the neutrophil extracellular trap-driven microvascular inflammation essential for diabetes vasculopathy?
  113. Abstracts
  114. Metabolic memory phenomenon in diabetes mellitus: Achieving and perspectives
  115. EuroHeartCare 2016
  116. Relation of osteoprotegerin level and numerous of circulating progenitor mononuclears in patients with metabolic syndrome
  117. Pattern of endothelial progenitor cells and apoptotic endothelial cell-derived microparticles in chronic heart failure patients with preserved and reduced left ventricular ejection fraction
  118. Circulating thrombospondin-2 in patients with moderate-to-severe chronic heart failure due to coronary artery disease
  119. The pattern of circulating microparticles in patients with diabetes mellitus with asymptomatic atherosclerosis
  120. The Neutrophil Extracellular Traps: The Missed Link between Microvascular Inflammation and Diabetes?
  121. Pattern of circulating endothelial-derived microparticles among chronic heart failure patients with dysmetabolic comorbidities: The impact of subclinical hypothyroidism
  122. Impaired Immune Phenotype of Endothelial Cell-derived Micro Particles: The Missing Link between Diabetes-related States and Risk of Cardiovascular Complications?
  123. The Role of Circulating Myeloid-Related Protein Complex Calprotectin in Prediction of Heart Failure with Preserved Ejection Fraction
  124. The Rationality to Use of Galectin-3 as Target in Biomarker-Guided Therapy of Type 2 Diabetes Mellitus
  125. The Biomarker Utility in Risk Stratification in an Ambulatory Heart Failure: ST2 or Galectin-3?
  126. Prognostication in Different Heart Failure Phenotypes: The Role of Circulating Biomarkers
  127. Aortic Stenosis: Predictive Value of Cardiac Biomarkers in Older Patients
  128. Does Visfatin Predict Cardiovascular Complications in Metabolic Syndrome Patients?
  129. Extracellular vesicles as novel delivery drug system in heart failure: from bench to bedside?
  130. Elevated galectin-3 level predicts pulmonary artery hypertension
  131. Molecular and biochemical mechanisms of mitochondrial dysfunction in spontaneously hypertensive rats
  132. Predictive value of vistafin in metabolic syndrome patients: focus on cardiovascular complications
  133. Single sample and serial measurements of osteoprotegerin level as a target of therapy in type 2 diabetes mellitus?
  134. Circulating endothelial-derived apoptotic microparticles and insulin resistance in non-diabetic patients with chronic heart failure
  135. Determination of early tumoricidal drug-induced cardiotoxicity with biological markers
  136. Can Osteoprotegerin be a Target of Therapy in Type 2 Diabetes Mellitus?
  137. Non-Classical Progenitor Mononuclears in Metabolic Syndrome: The Role of Serum 25-Hydroxyvitamin D3
  138. Impaired Pattern of Endothelial Cell-Derived Microparticles in Heart Failure Patients with Preserved and Reduced Left Ventricular Ejection Fraction
  139. Progenitor Endothelial Cell Dysfunction in Heart Failure: Clinical Implication and Therapeutic Target?
  140. Utilization of Novel Delivery Drug Systems Based on Release of Extracellular Vesicles in Heart Failure
  141. Global Longitudinal Strain and Strain Rate in Type Two Diabetes Patients with Chronic Heart Failure: Relevance to Osteoprotegerin
  142. Genetic Predictive Scores in Heart Failure: Possibilities and Expectations
  143. Progenitor Endothelial Cell Dysfunction in Obese Patients: Possibilities for Cardiovascular Risk Prediction
  144. Altered endothelial reparation and diabetes-Induced endothelial progenitor cell dysfunction
  145. Are Epigenetic Features Essential in Advance of Heart Failure Phenotypes?
  146. Blood pressure measurement assistance and antihypertensive drug compliance in older patients
  147. Circulating Vascular Endothelial Growth Factor-1 in Cardiovascular Disease
  148. Endothelial Repair in Diabetes: The Causative Role of Progenitor Cells Dysfunction?
  149. Epigenetic Mechanisms of Endothelial Progenitor Cell Dysfunction
  150. Epigenetic Modifications the Development of Different Heart Failure Phenotypes
  151. Epigenetically Modified Endothelial Progenitor Cells in Heart Failure
  152. Is Elevated Circulating Galectin-3 Level A Predictor of Pulmonary Artery Hypertension Development and Progression?
  153. Serum cystatin C and neutrophil gelatinase-associated lipocalin as biomarkers of glomerular and tubular kidney damage in patients with chronic glomerulonephritis and saved renal function
  154. Serum interleukin-18 as a biomarker of tubular kidney damage in patients with chronic glomerulonephritis
  155. The Cell-Free Mitochondrial DNA: A Novel Biomarker of Cardiovascular Risk?
  156. The Clinical Utility of Circulating Microparticles’ Measurement in Heart Failure Patients
  157. Endothelial Progenitor Cell Dysfunction as a Biomarker of Cardiovascular Risk in Obese Patients
  158. Different Obese Phenotypes and Progenitor Endothelial Cell Dysfunction: The Missed Link to Cardiovascular Risk
  159. Utility of the Red Blood Cell-Derived Microparticles as a Marker of Periprocedural Adverse Effects amongst Patients with Acute ST-Segment Elevation Myocardial Infarction
  160. The Endothelial Cell Secretome as a Factor of Endothelium Reparation: The Role of Microparticles
  161. The Promises, Methodological Discrepancies and Pitfalls in Measurement of Cell-Derived Extracellular Vesicles in Diseases
  162. The approaches to none-invasive detection of cell-derived extracellular vesicles
  163. The heart failure risk predictive scores based on the genetic features: hope and hype
  164. The risk stratification in heart failure patients: The controversial role of high-sensitive ST2
  165. The signature of circulating microparticles in heart failure patients with metabolic syndrome
  166. Biomarker-Guided Therapy for Chronic Heart Failure
  167. Endothelial progenitor cell-mediated vascular repair system in diabetes
  168. Pattern of circulating microparticles in chronic heart failure patients with metabolic syndrome: Relevance to neurohumoral and inflammatory activation
  169. Predictive value of circulating osteonectin in patients with ischemic symptomatic chronic heart failure
  170. Novel biomerker-based score for heart failure
  171. Predictive Value of Circulatingve-catherin in Coronary Artery Disease Patients with Symptomatic Moderate to Severe Chronic Heart Failure
  172. Stable Coronary Artery Disease Patients: Different Practice Patterns in Everyday Clinical Situations
  173. Endothelial Derived Micro Particles: Biomarkers for Heart Failure Diagnosis and Management
  174. Diabetes mellitus related biomarker: The predictive role of growth-differentiation factor-15
  175. Impaired phenotype of circulating endothelial microparticles in chronic heart failure patients: Relevance to body mass index
  176. The effect of angiotensin-2 receptor blocker valsartan on circulating level of endothelial progenitor cells in diabetic patients with asymptomatic coronary artery disease
  177. The Association of Subclinical Hypothyroidism and Pattern of Circulating Endothelial-Derived Microparticles Among Chronic Heart Failure Patients
  178. The Impact of Low-Grading Inflammation on Circulating Endothelial-Derived Progenitor Cells in Patients with Metabolic Syndrome and Diabetes Mellitus
  179. Impaired Immune Phenotype of Circulating Endothelial-Derived Microparticles in None-Diabetic Patients with Chronic Heart Failure: Impact on Insulin Resistance
  180. The predictive role of circulating microparticles in patients with chronic heart failure
  181. Predictive role of circulating endothelial-derived microparticles in cardiovascular diseases
  182. [PP.36.09]
  183. [PP.36.08]
  184. Moderated Poster Session 2: Sunday 3 May 2015, 15:30-16:30 * Room: Moderated Poster Area
  185. Poster Session 2: Monday 4 May 2015, 08:00-18:00 * Room: Poster Area
  186. Poster Session 3: Tuesday 5 May 2015, 08:30-12:30 * Room: Poster Area
  187. Predictive value of apoptotic microparticles to mononuclear progenitor cells ratio in advanced chronic heart failure patients
  188. Impaired immune phenotype of circulating endothelial-derived microparticles in patients with metabolic syndrome and diabetes mellitus
  189. Rational Synthesis of AB-Type N -Substituted Core-Functionalized Naphthalene Diimides (cNDIs)
  190. Содержание циркулирующих эндотелиальных прогениторных клеток у пациентов с хронической сердечной недостаточностью ишемической природы с сохраненной фракцией выброса левого желудочка
  191. Circulating Vascular Endothelial Growth Factor-1 in Cardiovascular Disease
  192. The association of serum osteoprotegerin/ sRANKL complex, C-reactive protein and adiponectin with number of circulating endothelial progenitor cells in patients with metabolic syndrome and diabetes mellitus
  193. The Role of Cardiac Biomarkers in Predicting of Mortality in Diabetic Patients
  194. The Development of Biological Molecular Sensing Techniques to detect Micro particles: Focus on Clinical Medicine Benefits
  195. Complications of Pharmacological Spasm Provocation Tests
  196. The Interplay of Aging, Aortic Stiffness and Blood Viscosity in Atherogenesis
  197. Transluminal endovascular aortic repair and pregnancy: a case report
  198. Inflammatory phenotype of circulating endothelial-derived microparticles in chronic heart failure patients with metabolic syndrome
  199. Micro RNA as Biomarkers and Tool for Target-Based Treatment in Patients with Inflammatory Bowel Diseases
  200. Immune Phenotypes of Endothelial-Derived Microparticles in Dysmetabolic Patients.
  201. Immune Phenotype of Circulating Endothelial-derived Microparticlesin Elderly Patients with Metabolic Syndrome and Diabetes Mellitus
  202. Vascular Endothelial Growth Factor-1 Level and Functional Neurologic Recovery after Ischemic Hemispheric Stroke
  203. The Metabolic Effects of Mineralocorticoid Receptor Antagonists in Heart Failure Patients
  204. Prognostication of heart failure development and advance: the role of high-sensitive ST2
  205. Impaired Phenotype of Circulating Endothelial-Derived Microparticles: Novel Marker of Cardiovascular Risk
  206. Circulating Cell-Free Mitochondrial DNA as Biomarker of Cardiovascular risk: New Challenges of Old Findings
  207. Biomarker-Guided Therapy for Chronic Heart Failure
  208. Bone-Related Proteins as Markers in Vascular Remodeling
  209. Utility of Biomarkers in Contemporary Management of Chronic Heart Failure
  210. Cardiovascular Biomarkers in Routine Screening of Diabetic Pati ents
  211. Early tumoricidal drug-induced cardiotoxicity determination: possibilities of biological markers
  212. The Pattern of Circulating Microparticles in Diabetes Mellitus Patients with Known Subclinical Atherosclerosis
  213. Signature of circulating endothelial-derived progenitor cells in patients with metabolic syndrome and diabetes mellitus
  214. Cell therapy of chronic heart failure: perspective of clinical approach
  215. The fixed combination of aliskiren and nebivolol in hypertensive patients: the clinical perspectives
  216. Impact of age on pattern of circulating endothelial-derived microparticles in heart failure patients
  217. Predictive Value of Circulating SPARC-Related protein Osteonectin in Patients with Symptomatic Moderate-to-Severe Ischemic-Induced Chronic Heart Failure
  218. The relationship between serum uric acid level and concentration of proangiogenic mononuclear progenitor cells in patients with chronic heart failure
  219. Relationship between circulating endothelial progenitor cells and insulin resistance in non-diabetic patients with ischemic chronic heart failure
  220. P202Interrelationship between circulating osteoprotegerin and subclinical coronary atherosclerosis in patients with type two diabetes mellitus
  221. P194Serum uric acid as independent predictor of decreased number of circulating proangiogenic progenitor cells in asymptomatic coronary artery disease patients
  222. Circulating Endothelial Progenitor Cells as Markers for Severity of Ischemic Chronic Heart Failure
  223. Impaired Pattern of Endothelial Derived Microparticles in Heart Failure Patients
  224. Diabetes mellitus and cellular replacement therapy: Expected clinical potential and perspectives
  225. Serum Uric Acid Predicts Declining of Circulating Proangiogenic Mononuclear Progenitor Cells in Chronic Heart Failure Patients
  226. Serum Rankl/Osteoprotegerin Complex and Endothelial Progenitor Cells in Chronic Heart Failure
  227. Predictive Value of Circulating Vascular Endothelial Growth Factor-1 Level Measured Repeatedly During Long-Term Follow-Up in Patients with Arterial Hypertension after Acute Ischemic Stroke
  228. Predictive Value of Circulating Apoptotic Microparticles in Patients with Ischemic Symptomatic Moderate-To-Severe Chronic Heart Failure
  229. Apoptotic Microparticles as Predicted Biomarkers in Patients with Chronic Heart Failure – Relevance to Inflammatory Cytokines and Outcomes
  230. C-reactive protein after stroke in arterial hypertension
  231. Vascular endothelial growth factor-1 as a predictor of unfavorable cardiovascular events in arterial hypertension patients after ischemic stroke
  232. Relationship between level of circulating endothelial progenitor cells and severity of ischemic chronic heart failure with preserved left ventricular ejection fraction
  233. Predict value of circulating bone-related glycopeptide osteoprotegerin in asymptomatic coronary artery disease patients with second type diabetes mellitus
  234. Predict value of circulating endothelial progenitor cells in patients with moderate-to-severe chronic heart failure due to coronary artery disease
  235. Circulating osteopontin as a marker of early coronary vascular calcification in type two diabetes mellitus patients with known asymptomatic coronary artery disease
  236. Analysis of Various Subsets of Circulating Mononuclear Cells in Asymptomatic Coronary Artery Disease
  237. Oral Abstract Session: Novel non-invasive risk marker
  238. Prognostic value of biological markers in myocardial infarction patients
  239. Circulating endothelial progenitor cells as a predictor of clinical outcomes in diabetic patients with symptomatic chronic heart failure
  240. A potential predict value of circulating osteoprotegerin in diabetic patients with asymptomatic coronary artery disease
  241. Serum Uric Acid as a Marker of Coronary Calcification in Patients with Asymptomatic Coronary Artery Disease with Preserved Left Ventricular Pump Function
  242. Predictive Value of Circulating Vascular Endothelial Growth Factor-1 in Arterial Hypertension Patients
  243. Bone-related circulating proteins as early predictors of coronary atherosclerosis in asymptomatic patients with known coronary artery disease
  244. Neuroprotective and memory enhancing properties of a dual agonist of the FGF receptor and NCAM
  245. Poster session 1
  246. Poster session 3
  247. TRANSFORMING GROWTH FACTOR-BETA 1 AND HEART REMODELING IN TYPE 2 DIABETES MELLITUS PATIENTS ASSOCIATED WITH LEFT VENTRICULAR DIASTOLIC DYSFUNCTION
  248. SIMVASTATIN IN ESCALATION DOSES IMPROVE RENAL FUNCTION IN PATIENTS WITH DIABETES MELLITUS AND MILD-TO-MODERATE PROTEINURIA
  249. OSTEOPONTIN PLASMA LEVEL AS A TARGET IN THE ASSESSMENT OF SEVERITY HEART FAILURE AND CARDIAC REMODELLING
  250. CIRCULATING STROMELYSIN-1 AS A POSSIBLE MARKER OF SEVERITY OF CARDIOVASCULAR REMODELING IN OBESITY PATIENTS AFTER MYOCARDIAL INFARCTION
  251. Abstracts
  252. Abstracts
  253. Saturday, 17 July 2010
  254. Candesartan cilexitil reduces neurohumoral and proinflammatory activation in patients with severe congestive heart failure
  255. 774 Highly selective beta-1 blocker bisoprolol significantly improves long-term prognosis in asymptomatic heart failure patients
  256. 724 Low doses of statins improve neurohumoral activity in patients with moderate-to-severe congestive heart failure due to coronary artery disease
  257. 313 The interrelation between plasma level of natriuretic peptide and long-term prognosis about patients with congestive heart failure
  258. 166 Angiotensin-2 receptor blockade with losartan improves left ventricular function at rest and post-exercise in heart failure patients with preserved ejection fraction
  259. 470 Angiotensin-2 receptor blockade with losartan improves left ventricular function at rest and post-exercise in heart failure patients with preserved ejection fraction
  260. Losartan in the Therapy of Heart Failure Patients
  261. 4.11 The interrelation between plasma level of atrial natriuretic peptide and long-term prognosis about patients with congestive heart failure
  262. 4.10 Long-term administration of angiotensin-2 receptor antagonist losartan adding to ace inhibitor enalapril in patients with congestive heart failure
  263. The dose-dependent influence of angiotensin-II receptor antagonist losartan on remodeling and neurohumoral status in patients with congestive heart failure
  264. Angiotensin-II receptor antagonist losartan improves the diastolic performance in patients with asymptomatic heart failure due to myocardial infarction
  265. Biological Markers and Guided Therapy